|1.||Park, Ju Youn: 4 articles (10/2008 - 01/2004)|
|2.||Kim, Soo-Ki: 3 articles (10/2008 - 02/2006)|
|3.||Kim, Yong Hae: 3 articles (02/2006 - 01/2004)|
|4.||Liu, Yan: 2 articles (08/2014 - 04/2011)|
|5.||Liu, Yang: 2 articles (08/2014 - 04/2011)|
|6.||Zheng, Pan: 2 articles (08/2014 - 04/2011)|
|7.||Wang, Yin: 2 articles (08/2014 - 04/2011)|
|8.||Ryang, Yong Suk: 2 articles (10/2008 - 02/2006)|
|9.||Shim, Kwang Yong: 2 articles (02/2006 - 08/2004)|
|10.||Kim, Soo Kie: 2 articles (08/2004 - 01/2004)|
08/14/2014 - "Importantly, in mice with complete remission, echinomycin appeared to completely eliminate LICs because no leukemia could be propagated in vivo following serial transplantation. "
08/01/1991 - "Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641."
04/08/2011 - "Importantly, the HIF-inhibitor echinomycin efficiently eradicated mouse lymphoma and serially transplantable human AML in xenogeneic models by preferential elimination of CSCs. "
12/01/2015 - "Moreover, the HIF-1α inhibitors, echinomycin, YC-1 and 2-methoxyestradiol, suppressed the proliferation of canine lymphoma cell lines. "
08/01/2013 - "Treatment with echinomycin suppressed cell growth and induced apoptosis in association with decreased mRNA expression of HIF1 targets, glucose transporter-1 (GLUT1) and B-cell CLL/lymphoma-2 (BCL2). "
|3.||Heterotopic Ossification (Ectopic Ossification)
08/01/1990 - "A phase II trial of echinomycin in metastatic cervix carcinoma."
08/01/1992 - "Echinomycin in this dose and schedule displays minimal activity in patients with advanced nonsquamous carcinoma of the cervix."
08/01/1992 - "Eighteen evaluable patients with recurrent or metastatic nonsquamous carcinoma of the uterine cervix were treated with 1,500 micrograms/m2 of echinomycin every 4 weeks. "
12/01/1987 - "Echinomycin was administered to patients with advanced carcinoma in escalating doses ranging from 60 to 1500 micrograms/m2 given weekly by 15-minute iv infusions for four doses, with a subsequent 2-week rest period. "
08/01/1990 - "Twenty-two patients with recurrent carcinoma of the ovary progressive after initial chemotherapy (21 with cisplatin-based treatment) were entered on a phase II trial utilizing Echinomycin at a dosage of 1,500 micrograms/m2 every 4 weeks. "
11/01/2007 - "These findings show, for the first time, that echinomycin has a dual effect on HIF-1 activity under normoxic and hypoxic conditions, demonstrating that this molecule cannot be used in cancer treatment."
12/01/1992 - "The story of echinomycin is of an antibiotic whose anti-cancer activity was rediscovered thanks to scientific investigation of its mode of action at the molecular level. "
05/01/1989 - "Echinomycin was administered to 43 patients with advanced cancer in escalating doses ranging from 60 to 2128 mcg/m2. "
01/01/1984 - "The overall in vitro response rates (defined as less than 50% survival of tumor colony-forming units) at three different doses of Echinomycin (0.001, 0.01, and 0.1 micrograms/ml) were between 16% and 19%. "
01/01/1984 - "A human tumor cloning system was utilized to screen for in vitro antitumor effects of the investigational anticancer agent Echinomycin. "
|2.||DNA (Deoxyribonucleic Acid)
|3.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Etoposide (VP 16)
|10.||vorinostat (suberoylanilide hydroxamic acid)
|1.||Transplantation (Transplant Recipients)
|2.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)